Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction

J Am Geriatr Soc. 2006 Mar;54(3):421-30. doi: 10.1111/j.1532-5415.2005.00635.x.

Abstract

Objectives: To characterize the relationship between hydroxymethylglutaryl-CoA reductase inhibitors (statins) and outcomes in older persons with acute myocardial infarction (AMI).

Design: Observational study.

Setting: Acute care hospitals in the United States from April 1998 to June 2001.

Participants: Medicare patients aged 65 and older with a principal discharge diagnosis of AMI (N=65,020) who did and did not receive a discharge prescription for statins.

Measurements: The primary outcome of interest was all-cause mortality at 3 years after discharge.

Results: Of 23,013 patients with AMI assessed, 5,513 (24.0%) were receiving a statin at discharge. Nearly 40% of eligible patients (n=8,452) were aged 80 and older, of whom 1,310 (15.5%) were receiving a statin at discharge. In a multivariable model taking into account demographic, clinical, physician and hospital characteristics, and propensity score, discharge statin therapy was associated with significantly lower 3-year mortality (hazard ratio (HR)=0.89 (95% confidence interval (CI)=0.83-0.96)). In an analysis stratified by age, discharge statins were associated with lower mortality in patients younger than 80 (HR=0.84, 95% CI=0.76-0.92) but not in those aged 80 and older (HR=0.97, 95% CI=0.87-1.09).

Conclusion: Statin therapy is associated with lower mortality in older patients with AMI younger than 80 but not in those aged 80 and older, as a group. This finding questions whether statin efficacy data in younger patients can be broadly applied to the very old and indicates the need for further study of this group.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Aged, 80 and over
  • Atorvastatin
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects
  • Drug Prescriptions
  • Fatty Acids, Monounsaturated / therapeutic use
  • Female
  • Fluvastatin
  • Follow-Up Studies
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Indoles / therapeutic use
  • Lovastatin / therapeutic use
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Odds Ratio
  • Pravastatin / therapeutic use
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Retrospective Studies
  • Survival Rate / trends
  • Treatment Outcome

Substances

  • Cholesterol, LDL
  • Fatty Acids, Monounsaturated
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Pyridines
  • Pyrroles
  • Fluvastatin
  • Lovastatin
  • Atorvastatin
  • cerivastatin
  • Pravastatin